Could This Send Moderna's Stock Soaring Back to $400?
Shares of Moderna (NASDAQ: MRNA) have been plummeting in recent months. Although the market as a whole hasn't done well, the healthcare stock's 43% decline this year is far worse than the 19% drop that the S&P 500 has endured over the same period. As concerns shift from COVID-19 and onto inflation, investors have become less bullish on Moderna's stock. It also doesn't help that Novavax could obtain Emergency Use Authorization for its vaccine any day now.
But there is a catalyst that could change the stock's fortunes, one that could extend the prospects of Moderna generating COVID-19 revenue for the foreseeable future.
One of the most frustrating things about COVID-19 is that there are so many variants to track. And it's difficult, if not impossible, to know which ones may cause serious problems for the world and which ones won't. Omicron was a significant variant when it emerged in November, and that prompted Moderna to create a booster shot which targeted that variant.
Source Fool.com
